enVVeno Medical (NVNO) Liabilities and Shareholders Equity (2017 - 2026)

enVVeno Medical has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $26.1 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 35.69% year-over-year to $26.1 million; the trailing twelve-month figure through Mar 2026 stood at $124.6 million (down 29.58% YoY), and the FY2025 full-year result was $29.6 million, down 34.24% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $26.1 million, down from $29.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $54.2 million in Q1 2022, with the low at $26.1 million in Q1 2026.
• Average Liabilities and Shareholders Equity over 5 years is $40.2 million, with a median of $41.0 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity sank 38.2% in 2023 and soared 79.36% in 2024.
• Tracing NVNO's Liabilities and Shareholders Equity over 5 years: stood at $41.7 million in 2022, then rose by 16.74% to $48.6 million in 2023, then slipped by 7.57% to $45.0 million in 2024, then slumped by 34.24% to $29.6 million in 2025, then retreated by 11.72% to $26.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $26.1 million (Q1 2026), $29.6 million (Q4 2025), and $32.4 million (Q3 2025), per Business Quant data.

Peer Comparison